All aboard the pub­lic fi­nanc­ing train! Zen­tal­is, Ed­i­tas, Ve­rastem, Prax­is and Clene, among oth­ers, raise funds

Biotechs left and right an­nounced stock sales this week af­ter da­ta drops at AS­CO, the Eu­ro­pean Hema­tol­ogy As­so­ci­a­tion’s an­nu­al meet­ing and else­where.

The famed genome edit­ing biotech Ed­i­tas Med­i­cine seeks about $125 mil­lion. Zen­tal­is Phar­ma­ceu­ti­cals wants dou­ble that. Ve­rastem On­col­o­gy eyes $85 mil­lion. The tal­ly for Prax­is Pre­ci­sion Med­i­cines is $59.1 mil­lion. And over at Clene, the fig­ure is $40 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER